Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with ...

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with expanded ...

In January, Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for ...

The firm’s confidence in the stock is supported by the strong performance of Guardant Health’s G360 core, the growing momentum of the Reveal test, and the potential of the Shield test in the ...

The firm’s confidence in the stock is supported by the strong performance of Guardant Health’s G360 core, the growing momentum of the Reveal test, and the potential of the Shield test in the market.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved ...